Top Stories
The fresh capital will help NOUS-209 move into a registration-enabling study for cancer interception in Lynch syndrome carriers.
The treatment was previously approved for pharmacologically-induced mydriasis in 2023.
Some cell and gene therapy processing platforms will be banned from exportation, while target-discovery related technologies may be exported if given a regulatory green light.
The EMA's Committee for Medicinal Products for Human Use also recommended approval of Revolution Medicines' pancreatic cancer drug.
The funding will help the biotech move its two lead programmes into the clinic for autosomal dominant polycystic kidney disease in 2027 and 2028, respectively.
Conference News
Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentationsSignatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 mill...
First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line data for olom...
• Phase 1 interim study for SB27, a proposed biosimilar to Keytruda (pembrolizumab), demonstrates its pharmacokinetic bioequivalence, comparable efficacy and safety to reference pembrolizumab in resec...
BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Canc...
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through nex...
